Anti-CD 19 and anti-CD 20 CAR-modified T cells for B-cell malignancies: a systematic review and meta-analysis

Author:

Riaz Irbaz Bin1,Zahid Umar1,Kamal Muhammad Umar2,Husnain Muhammad1,McBride Ali3,Hua Anh4,Hamadani Auon Abbas1,George Laeth5,Zeeshan Ali6,Sipra Qurat-ul-Ain Riaz1,Raina Ammad7,Rahman Bushra5,Puvvada Soham1,Anwer Faiz1

Affiliation:

1. University of Arizona, Department of Medicine, Hematology & Oncology, Tucson, AZ, 85724 USA

2. Department of Medicine, Bronx Lebanon Hospital, Icahn School of Medicine at Mount Sinai, Bronx, NY 10457 USA

3. University of Arizona, College of Pharmacy, Tucson, AZ, USA

4. University of Arizona, Department of Pharmacology and Toxicology, Tucson, AZ, 85724 USA.

5. University of Arizona, College of Medicine, Phoenix, AZ, 85004, USA

6. Tucson Medical Center, Department of Medicine, Tucson Medical Center, Tucson, AZ, 85712, USA

7. Canyon Vista Medical Centre, Department of Medicine, Sierra Vista, AZ, 85635, USA

Abstract

Chimeric antigen receptor modified T cells targeting CD19 and CD20 have shown activity in Phase I, II trials of patients with hematological malignancies. We conducted a systematic review and meta-analysis of all published clinical trials studying the role of efficacy as well as safety of CD-19 and CD-20 chimeric antigen receptor-T therapy for B-cell hematologic malignancies. A total of 16 studies with 195 patients were identified. The pooled analysis showed an overall response rate of 61% (118/195) with complete response of 42% (81/195) and partial response of 19% (37/195). Major adverse events were cytokine release syndrome 33%, neurotoxicity 33% and B-cell aplasia 54%. Collectively, the results indicate encouraging response in relapsed/refractory B lymphoma and leukemia, especially in acute lymphoblastic leukemia (ALL) patients.

Publisher

Future Medicine Ltd

Subject

Oncology,Immunology,Immunology and Allergy

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3